[1] | Holick MF (2007). Vitamin D deficiency. N Engl J Med, 357: 266-281. |
[2] | Lackland DT and Weber MA (2015). Global burden of cardiovascular cure disease and stroke: hypertension at the core. Can J Cardiol, 31: 569-571. |
[3] | Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. (2008). Vitamin D deficiency and risk of cardiovascular disease. Circulation, 117(4): 503-511. |
[4] | Forman JP, Curhan GC and Taylor EN (2008). Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension, 52(5): 828-832. |
[5] | Judd SE, Nanes MS, Ziegler TR, Wilson PW and Tangpricha V (2008). Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr, 87(1): 136-141. |
[6] | Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey (2007). Am J Hypertens, 20(7): 713-719. |
[7] | Sypniewska G, Pollak J, Strozecki P, Camil F, Kretowicz M, Janikowski G, et al. (2014). 25-hydroxyvitamin D, biomarkers of endothelial dysfunction and subclinical organ damage in adults with hypertension. Am J Hypertens, 27(1): 114-121. |
[8] | Lind L, Wengle B and Ljunghall S (1987). Blood pressure is lowered by vitamin D (alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A double-blind, placebo-controlled study. Acta Med Scand, 222(5): 423-427. |
[9] | Lind L, Wengle B, Wide L, Sörensen OH and Ljunghall S (1988). Hypertension in primary hyperparathyroidism--reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A double-blind, placebo-controlled study. Am J Hypertens, 1(4 Pt 1): 397-402. |
[10] | Zittermann A (2006). Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol, 92(1): 39–48. |
[11] | Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. (2009). Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int, 20(11): 1807-1820. |
[12] | Scragg R, Khaw KT and Murphy S (1995). Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr, 49(9): 640-646. |
[13] | Tamez H and Thadhani RI (2012). Vitamin D and hypertension: An update and review. Curr Opin Nephrol Hypertens, 21(5): 492–499. |
[14] | Frohlich ED, González A and Díez J (2011). Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. J Hypertens, 29(1): 17–26. |
[15] | Schluter KD and Piper HM (1992). Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol, 263(6 Pt 2): H1739-H1746. |
[16] | Perkovic V, Hewitson TD, Kelynack KJ, Martic M, Tait MG and Becker GJ (2003). Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res, 26(1): 27-33. |
[17] | Staessen JA, Wang JG and Thijs L (2003). Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens, 21(6): 1055-1076. |
[18] | Levy D, Salomon M, D’Agostino RB, Belanger AJ and Kannel WB (1994). Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 90(4): 1786–1793. |
[19] | Kuznetsova T and Cauwenberghs N (2016). Heart Failure and Hypertension. In: Dorobanţu M., Ruschitzka F., Metra M. (eds) Current Approach to Heart Failure. Springer, Cham. p. 437–454. |
[20] | Aloia JF, Feuerman M and Yeh JK (2006). Reference range for serum parathyroid hormone. Endocr Pract, 12(2): 137–144. |
[21] | Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE and Roccella EJ (2008). Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension, 52(5): 818–827. |
[22] | Lavie CJ, Dinicolantonio JJ, Milani RV and O’Keefe JH (2013). Vitamin D and cardiovascular health. Circulation, 128(22): 2404–2406. |
[23] | Hintzpeter B, Mensink GB, Thierfelder W, Muller MJ and Scheidt-Nave C (2008). Vitamin D status and health correlates among German adults. Eur J Clin Nutr, 62(9): 1079–1089. |
[24] | Fraser A, Williams D and Lawlor DA (2010). Associations of serum 25-hydroxyvitamin D, parathyroid hormone and calcium with cardiovascular risk factors: analysis of 3 NHANES cycles (2001-2006). PLoS One, 5(11): e13882. |
[25] | Okamoto LE, Gamboa A, Shibao C, Black BK, Diedrich A, Raj SR, et al. (2009). Nocturnal blood pressure dipping in the hypertension of autonomic failure. Hypertens, 53(2): 363–369. |
[26] | Wong MS, Delansorne R, Man RY and Vanhoutte PM (2008). Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol, 295(1): H289-H296. |
[27] | Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J and Rashid G (2008). Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol, 294(5): F1059-F1064. |
[28] | Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J, 39(33): 3021-3104. |
[29] | Fava C, Burri P, Almgren P, Arcaro G, Groop L, Lennart Hulthén U and Melander O (2005). Dipping and variability of blood pressure and heart rate at night are heritable traits. Am J Hypertens, 18(11): 1402-1407. |
[30] | Ogunlade O and Akintomide AO (2013). Assessment of voltage criteria for left ventricular hypertrophy in adult hypertensives in south-western Nigeria. J Cardiovasc Dis Res, 4(1): 44-46. |
[31] | Ibrahim MM and Damasceno A (2012). Hypertension in developing countries. Lancet, 380(9841): 611–619. |
[32] | Ingle VV (2017). Study of diastolic dysfunction in essential hypertension patients in relation to age and duration of treatment. Int J Adv Med, 4(5): 1447–1450. |
[33] | Akintunde AA, Akinwusi PO, Familoni OB and Opadijo OG (2010). Effect of systemic hypertension on right ventricular morphology and function: an echocardiographic study. Cardiovasc J Afr, 21(5): 252–256. |
[34] | Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL and Folsom AR (2008). The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol, 52(25): 2148-2155. |
[35] | Pilz S, Kienreich K, Tomaschitz A, Lerchbaum E, Meinitzer A, März W, et al. (2012). Vitamin D and cardiovascular disease: update and outlook. Scand J Clin Lab Invest Suppl, 243: 83-91. |
[36] | Ullah MI, Uwaifo GI, Nicholas WC and Koch CA (2009). Does vitamin d deficiency cause hypertension? Current evidence from clinical studies and potential mechanisms. Int J Endocrinol, 2010: 579640. |
[37] | Fallo F, Catena C, Camozzi V, Luisetto G, Cosma C, Plebani M, et al. (2012). Low serum 25-hydroxyvitamin D levels are associated with left ventricular hypertrophy in essential hypertension. Nutr Metab Cardiovasc Dis, 22(10): 871-876. |
[38] | Stolarz-Skrzypek K, Olszanecka A, Wojciechowska W, Czarnecka D (2014). Association of serum vitamin D with left ventricular hypertrophy in hypertensive patients. J Am Soc Hypertens, 8(4): e65. |
[39] | Chandana SR, Kocharla LP, Harris SS and Kakarala RR (2009). Association of vitamin D deficiency with hypertension in uninsured women. J Health Dispar Res Pract, 3(1): 43–52. |
[40] | Burgaz A, Orsini N, Larsson SC and Wolk A (2011). Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens, 29: 636–645. |
[41] | Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ and Curhan GC (2005). Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension, 46(4): 676–682. |
[42] | Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. (2005). Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab, 288(1): E125-E132. |
[43] | Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, et al. (2005). 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation, 111(13): 1666-1671. |
[44] | Birkenhäger AM and van den Meiracker AH (2007). Causes and consequences of a non-dipping blood pressure profile. Neth J Med, 65(4): 127-131. |
[45] | Abdel Rahman MA, Galal H and Omar AMS (2015). Correlation between serum vitamin D level and cardiac function: Echocardiographic assessment. Egypt Hear J, 67: 299–305. |
[46] | Näppi S, Saha H, Virtanen V, Limnell V, Sand J, Salmi J and Pasternack A (2000). Left ventricular structure and function in primary hyperparathyroidism before and after parathyroidectomy. Cardiology, 93(4): 229-233. |
[47] | Ali HAH, Mohamad NAR, Mohammad HSE, Abdul Hamid SK (2016). 2-D Speckle tracking in the assessment of left and right ventricular functions in hemodialysis versus recently diagnosed uremic patients with preserved systolic function. Egypt J Crit Care Med, 4(3): 139-144. |
[48] | Andersson P, Rydberg E and Willenheimer R (2004). Primary hyperparathyroidism and heart disease--a review. Eur Heart J, 25(20): 1776-1787. |